Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Summary

This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.

Eligibility

Inclusion Criteria:

* Participants with histologically or cytologically confirmed ES-SCLC.
* Fully understand the study and voluntarily sign the informed consent form;
* Male or female 18\~75 years of age;
* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
* Life expectancy ≥ 3 months;

Exclusion Criteria:

* Participants were deemed unsuitable for participating in the study by the investigator for any reason.

Conditions3

Interventions2

Related trials

• A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy — Fudan University
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC — Shanghai Henlius Biotech
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors — Shanghai Henlius Biotech
• A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study — Fudan University
• Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer — Fudan University
• Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC — Fujian Medical University Union Hospital
• Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer — Tang-Du Hospital
• Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma — Zekuan Xu

Browse More Trials